Logo image of LEXX

LEXARIA BIOSCIENCE CORP (LEXX) Stock Price, Quote, News and Overview

NASDAQ:LEXX - Nasdaq - US52886N4060 - Common Stock - Currency: USD

1.08  +0.02 (+1.89%)

LEXX Quote, Performance and Key Statistics

LEXARIA BIOSCIENCE CORP

NASDAQ:LEXX (5/9/2025, 8:05:19 PM)

1.08

+0.02 (+1.89%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High4.44
52 Week Low1.01
Market Cap21.04M
Shares19.48M
Float18.11M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-10 2025-07-10
IPO10-28 2009-10-28


LEXX short term performance overview.The bars show the price performance of LEXX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

LEXX long term performance overview.The bars show the price performance of LEXX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 -60

The current stock price of LEXX is 1.08 USD. In the past month the price decreased by -19.4%. In the past year, price decreased by -69.58%.

LEXARIA BIOSCIENCE CORP / LEXX Daily stock chart

LEXX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 53.38 696.37B
JNJ JOHNSON & JOHNSON 15.35 371.06B
NVO NOVO-NORDISK A/S-SPONS ADR 18.9 291.96B
NVS NOVARTIS AG-SPONSORED ADR 13.08 214.69B
AZN ASTRAZENECA PLC-SPONS ADR 18.16 209.49B
MRK MERCK & CO. INC. 9.75 191.17B
PFE PFIZER INC 6.94 126.36B
SNY SANOFI-ADR 13.1 122.16B
BMY BRISTOL-MYERS SQUIBB CO 6.33 94.53B
GSK GSK PLC-SPON ADR 6.69 74.10B
ZTS ZOETIS INC 26.46 71.04B
HLN HALEON PLC-ADR 22.38 48.43B

About LEXX

Company Profile

LEXX logo image Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 7 full-time employees. The company went IPO on 2009-10-28. The firm's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The company is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. The company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.

Company Info

LEXARIA BIOSCIENCE CORP

100 - 740 Mccurdy Road

Kelowna BRITISH COLUMBIA V1X 2P7 CA

CEO: Christopher Bunka

Employees: 5

LEXX Company Website

LEXX Investor Relations

Phone: 12507656424

LEXARIA BIOSCIENCE CORP / LEXX FAQ

What is the stock price of LEXARIA BIOSCIENCE CORP today?

The current stock price of LEXX is 1.08 USD. The price increased by 1.89% in the last trading session.


What is the ticker symbol for LEXARIA BIOSCIENCE CORP stock?

The exchange symbol of LEXARIA BIOSCIENCE CORP is LEXX and it is listed on the Nasdaq exchange.


On which exchange is LEXX stock listed?

LEXX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LEXARIA BIOSCIENCE CORP stock?

7 analysts have analysed LEXX and the average price target is 7.14 USD. This implies a price increase of 561.11% is expected in the next year compared to the current price of 1.08. Check the LEXARIA BIOSCIENCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LEXARIA BIOSCIENCE CORP worth?

LEXARIA BIOSCIENCE CORP (LEXX) has a market capitalization of 21.04M USD. This makes LEXX a Nano Cap stock.


How many employees does LEXARIA BIOSCIENCE CORP have?

LEXARIA BIOSCIENCE CORP (LEXX) currently has 5 employees.


What are the support and resistance levels for LEXARIA BIOSCIENCE CORP (LEXX) stock?

LEXARIA BIOSCIENCE CORP (LEXX) has a resistance level at 1.49. Check the full technical report for a detailed analysis of LEXX support and resistance levels.


Is LEXARIA BIOSCIENCE CORP (LEXX) expected to grow?

The Revenue of LEXARIA BIOSCIENCE CORP (LEXX) is expected to grow by 51.14% in the next year. Check the estimates tab for more information on the LEXX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LEXARIA BIOSCIENCE CORP (LEXX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LEXARIA BIOSCIENCE CORP (LEXX) stock pay dividends?

LEXX does not pay a dividend.


When does LEXARIA BIOSCIENCE CORP (LEXX) report earnings?

LEXARIA BIOSCIENCE CORP (LEXX) will report earnings on 2025-07-10.


What is the Price/Earnings (PE) ratio of LEXARIA BIOSCIENCE CORP (LEXX)?

LEXARIA BIOSCIENCE CORP (LEXX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.58).


What is the Short Interest ratio of LEXARIA BIOSCIENCE CORP (LEXX) stock?

The outstanding short interest for LEXARIA BIOSCIENCE CORP (LEXX) is 3.21% of its float. Check the ownership tab for more information on the LEXX short interest.


LEXX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LEXX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to LEXX. LEXX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LEXX Financial Highlights

Over the last trailing twelve months LEXX reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 14.71% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -108.13%
ROE -131.33%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-150%
Sales Q2Q%20%
EPS 1Y (TTM)14.71%
Revenue 1Y (TTM)36.14%

LEXX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to LEXX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -29.72% and a revenue growth 51.14% for LEXX


Ownership
Inst Owners8.04%
Ins Owners7.81%
Short Float %3.21%
Short Ratio4.65
Analysts
Analysts82.86
Price Target7.14 (561.11%)
EPS Next Y-29.72%
Revenue Next Year51.14%